The Antidote - Summer 2016
Welcome to the Summer 2016 edition of The Antidote, our lifesciences sector bulletin.
In this edition, we look at:
- the new Market Abuse Regulation (MAR) which comes in to effect on 3 July
the European General Court’s judgement on generic market entry relative to orphan medicinal products;
diligence obligations in licence agreements; and
- the impact of new procurement rules on lifesciences organisations.
If you would like to discuss any of these topics in more detail, please get in touch with Sarah Hanson, Head of UK Lifesciences, or the authors of the articles.